Ensysce Biosciences

Ensysce Biosciences EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ensysce Biosciences (ENSC) as of Oct 20, 2026 is -10.24 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -6.73 M USD — a change of 52.17% (lower).

EBITDA

-10.24 MUSD

YoY

52.17%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ensysce Biosciences is 2025 -10.24 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ensysce Biosciences was 2024 -6.73 M USD. It decreases by 52.17% lower compared to the previous year.

The Ensysce Biosciences EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-959,240.00 USD
Jan 1, 2019
-3.33 M USD
Jan 1, 2020
-1.61 M USD
Jan 1, 2021
-19.87 M USD
Jan 1, 2022
-24.22 M USD
Jan 1, 2023
-10.72 M USD
Jan 1, 2024
-6.73 M USD
Jan 1, 2025
-10.24 M USD
The Ensysce Biosciences EBITDA history
YEAREBITDAYoY
-10.24 MUSD+52.17%
-6.73 MUSD-37.21%
-10.72 MUSD-55.75%
-24.22 MUSD+21.90%
-19.87 MUSD+1,131.67%
-1.61 MUSD-51.53%
-3.33 MUSD+247.01%
-959,240.00USD+552.54%
-147,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ensysce Biosciences Stock analysis

What does Ensysce Biosciences do? Ensysce Biosciences Inc, based in La Jolla, California, is a clinical-stage biopharmaceutical company operating in the Health Care sector. It develops innovative solutions for severe pain relief with reduced risk of opioid misuse, abuse, and overdose. The company utilizes proprietary technology platforms, including TAAP for abuse-resistant opioids and MPAR for overdose protection, to create safer prescription drugs. With 7 employees, it focuses on advancing its pipeline of novel drug platforms to address critical challenges in pain management. Ensysce Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ensysce Biosciences stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ensysce Biosciences is -10.24 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Ensysce Biosciences changed from -6.73 M USD to -10.24 M USD, representing a 52.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Ensysce Biosciences since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Ensysce Biosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Ensysce Biosciences

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Ensysce Biosciences